The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
Open Access
- 28 February 2013
- journal article
- research article
- Published by Elsevier BV in Cancer Genetics
- Vol. 206 (1-2), 26-31
- https://doi.org/10.1016/j.cancergen.2012.12.003
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeJNCI Journal of the National Cancer Institute, 2012
- Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutationsJournal of Clinical Pathology, 2011
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human CancerCancer Research, 2010
- Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutationCancer and Metastasis Reviews, 2010
- KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I TherapyAnnals of Surgical Oncology, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Mutational Activation of the K-rasOncogeneThe New England Journal of Medicine, 1987